Network Insights Methodology Whitepaper Get Access

Novartis

ORG Health Care / Pharmaceuticals Momentum 10.3ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. CRITICALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$94.3B market cap (Basel) advancing molecular glue degrader and RNA medicine pipelines through partner deals and internal development. Struck second $40M upfront agreement with Orionis Biotherapeutics; RNA therapeutic from 2018 AveXis acquisition building regulatory case as first-in-class for rare muscle disease.

Second molecular glue degrader deal with Orionis Biotherapeutics ($40M upfront); part of strategic doubling-down on molecular glue platform. RNA medicine program from $12B AveXis acquisition advancing in rare muscular dystrophy.
0.05
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
10.3
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
27
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Novartis is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
Pfizer Merck China European Union PlocamiumAI United States Anthropic AstraZeneca CEO North Carolina Eli Lilly Texas DOD Senator Roche
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-18 2026-06-17 27 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
429.102
Sentiment-Momentum Divergence
0.000
Source Concentration
0.791
Signal
Novartis is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #29 of 87 in Health Care — in line with sector peers. PSI stable vs yesterday (-0.02).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
29 of 87
Sector Rank
+0.35
Peer Z-Score
67%
Sector Percentile
Network Analysis
27 Degree Centrality
Ego Network (top connections)
Pfizer (weight 92.0)Merck (weight 91.0)China (weight 7.0)European Union (weight 7.0)PlocamiumAI (weight 7.0)United States (weight 7.0)Anthropic (weight 5.0)AstraZeneca (weight 4.0) PfizerMerckChinaEuropean UnionPlocamiumAIUnited StatesAnthropicAstraZeneca Novartis (degree 27) Novartis
Centrality History
2026-05-18 2026-06-17 27 0 Degree Mentions
EntityWeight StatusFirst Seen
Pfizer 92 NEW
Merck 91 NEW
China 7 NEW
European Union 7 NEW
PlocamiumAI 7 NEW
United States 7 NEW
Anthropic 5 NEW
AstraZeneca 4 NEW
CEO 4 NEW
North Carolina 4 NEW
Eli Lilly 3 NEW
Texas 3 NEW
DOD 3 NEW
Senator 2 NEW
Roche 2 NEW
Germany 2 NEW
United Kingdom 2 NEW
Boeing 2 NEW
Intel 2 NEW
Ohio 2 NEW
SEC 2 NEW
TSMC 2 NEW
FDA 2 NEW
Airbus 2 NEW
Asia 2 NEW
BP 2 NEW
Barclays 2 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-06-17 ← Intelligence Network